

School Committee on Faculty Conduct, ORI found that Eric T. Fossel, Ph.D., former Harvard Medical School Associate Professor of Radiology at Beth Israel Hospital, committed scientific misconduct by reporting falsified research results in a Public Health Service (PHS) grant application.

Specifically, Dr. Fossel altered nuclear magnetic resonance (NMR) data in the Multicenter Breast Trial (MCBT) such that the NMR test, purporting to detect from a patient's blood sample a predisposition toward malignancy or a relapse, appeared to be more accurate, sensitive, and specific than was actually the case. Premised on these falsely reported results, Dr. Fossel proposed in a PHS grant application that the National Cancer Institute provide funds to complete the MCBT.

Dr. Fossel has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning May 9, 1996, to exclude himself from:

(1) any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations), and

(2) serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

No scientific publications were required to be corrected as part of this Agreement.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 96-14389 Filed 6-6-96; 8:45 am]

BILLING CODE 4160-17-P

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Teleconference Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative

Agreements for Prevention Centers/National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 1, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.-5 p.m., June 24, 1996.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, "Cooperative Agreements for Prevention Centers/NCCDPHP—General Special Interest Projects."

Contact Person for More Information:

James E. Barrow, Deputy Director, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/488-5269.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Centers Program/NCCDPHP—General Special Interest Projects, Panel Number 2, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.-5 p.m., June 25, 1996.

Place: NCCDPHP, CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, "Cooperative Agreements for Prevention Centers/NCCDPHP—General Special Interest Projects."

Contact Person for More Information:

Michael N. Waller, Program Manager, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/488-5292.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Centers Program/NCCDPHP—General Special Interest Projects, Panel Number 3, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.-5 p.m., June 26, 1996.

Place: NCCDPHP, CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Considered: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, "Cooperative Agreements for Prevention Centers/NCCDPHP—General Special Interest Projects."

Contact Person for More Information: Craig L. Leutzinger, Public Health Advisor, Division of Adult and Community Health,

NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/488-5304.

These meetings will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92-463.

Dated: May 31, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-14381 Filed 6-6-96; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

Advisory Committee Meeting; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is cancelling the meeting of the Science Board to the Food and Drug Administration scheduled for June 13, 1996, to provide time for the agency to continue its development of strategies to address toxicity, carcinogenicity, and biomaterials testing. The meeting was announced in the Federal Register of May 24, 1996 (61 FR 26187).

FOR FURTHER INFORMATION CONTACT: Susan A. Homire, Office of Science (HF-33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3340; or call the FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572) in the Washington, DC area, Science Board to the Food and Drug Administration, code 12603.

Dated: June 3, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96-14388 Filed 6-06-96; 8:45 am]

BILLING CODE 4160-01-F

Memorandum of Understanding Between the Food and Drug Administration and the U.S. Department of Agriculture and the Russian Federation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the U.S. Department of Agriculture and